EDWARDS LIFESCIENCES CORP

Edwards Lifesciences insider trades reveal executive confidence as the company drives high‑margin TAVR growth, value‑based pricing, and global expansion.

Edwards Lifesciences boosts its 2026 outlook after acquiring Autus Valve Technologies, adding high‑growth mitral and tricuspid products to its TAVR‑heavy portfolio and projecting 12% revenue growth and 18% EBITDA lift—while navigating regulatory, re…

Edwards Lifesciences insider trading filings reveal executive confidence and disciplined equity‑compensation compliance, offering investors insight into strategic liquidity and long‑term growth.

Edwards Lifesciences insider filings show routine COO equity trades—options, sales, Rule 144 compliance—highlighting typical medical‑device executive liquidity and transparency.

Edwards Lifesciences insider trades reveal how Rule 144 sales and employee options uphold governance and investor confidence in the cardiovascular device sector.

Edwards Lifesciences sees modest institutional share moves amid a market‑wide valuation slowdown, yet maintains strong earnings, cash flow, and growth prospects for investors.

Edwards Lifesciences sharpens its balance sheet, secures $120 M convertible debt for a low‑cost polymer mitral valve, and shows disciplined equity activity—boosting financial health while targeting LMI markets.

Edwards Lifesciences Q1 2026 earnings show modest EPS growth and a 7.3 % revenue rise driven by valve sales and a critical‑care rebound.

Edwards Lifesciences’ Q1 2026 earnings outlook shows 12–15% revenue growth and 34–36% margins, powered by proven safety, efficacy, and regulatory success of its TAVR, MitraClip XTR and Triclip devices.

Edwards Lifesciences dominates the minimally invasive heart‑valve market with proven safety, 90%+ 5‑year durability, and a positive one‑year ROI, making it a top choice for investors and clinicians alike.